# Pyxis Oncology to Participate in Upcoming Investor Conferences Canonical URL: https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-upcoming-investor-conferences-1efc2076 Ticker: PYXS Company: Pyxis Oncology Source: Pyxis Oncology Published: 2026-09-01 11:30 EST ## Summary Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for... ## Article Body Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences. Wells Fargo 21 st Annual Healthcare Conference in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET. 2026 Cantor Global Healthcare Conference in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET. H.C. Wainwright 28 th Annual Global Investment Conference in New York, NY on Monday, September 14, 2026, at 9:30 a.m. ET. Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com . About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment. MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. To learn more, visit www.pyxisoncology.com or follow us on LinkedIn . Pyxis Oncology Contact IR@pyxisoncology.com ## Recent Company News - 2026-09-01 11:30 EST — [Pyxis Oncology to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-upcoming-investor-conferences-1efc2076) — Source: Pyxis Oncology - 2026-08-13 11:00 EST — [Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones](https://biopharmsignal.com/news/PYXS/pyxis-oncology-reports-second-quarter-2026-financial-results-and-advances-micvo--854d08bd) — Source: Pyxis Oncology - 2026-06-30 11:30 EST — [Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones](https://biopharmsignal.com/news/PYXS/pyxis-oncology-announces-up-to-114-million-private-placement-financing-to-advanc-a7414ffd) — Source: Pyxis Oncology - 2026-05-14 11:00 EST — [Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones](https://biopharmsignal.com/news/PYXS/pyxis-oncology-reports-first-quarter-2026-financial-results-and-advances-micvo-t-3b0d67d9) — Source: Pyxis Oncology - 2026-05-13 11:30 EST — [Pyxis Oncology to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-upcoming-investor-conferences-c593dd86) — Source: Pyxis Oncology ## Related News - 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553) - 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd) - 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f) - 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e) - 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)